[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Parabilis Medicines Inc (PBLS)

Parabilis Medicines Inc (PBLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,397,395
  • Shares Outstanding, K 118,146
  • Annual Sales, $ 0 K
  • Annual Income, $ -145,889 K
  • EBIT $ 0 M
  • EBITDA $ 0 M
  • 60-Month Beta N/A
  • Price/Sales 30,702.08
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings $-2.13 on 08/13/26
  • Next Earnings Date 11/12/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 75.00% (-8.97%)
  • Historical Volatility 58.96%
  • IV Percentile 30%
  • IV Rank 38.95%
  • IV High 90.39% on 07/22/26
  • IV Low 65.19% on 07/21/26
  • Expected Move (DTE 3) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.63
  • Today's Volume 13
  • Volume Avg (30-Day) 16
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 289
  • Open Int (30-Day) 108
  • Expected Range 37.22 to 37.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.35
  • Number of Estimates 2
  • High Estimate $-0.25
  • Low Estimate $-0.45
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.42 +40.88%
on 07/20/26
38.83 -4.13%
on 08/17/26
+7.67 (+25.96%)
since 07/17/26

Most Recent Stories

More News
Parabilis Medicines: Q2 Earnings Snapshot

Parabilis Medicines: Q2 Earnings Snapshot

PBLS : 37.22 (+0.40%)
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors  Announced strategic research collaboration...

PBLS : 37.22 (+0.40%)
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing...

PBLS : 37.22 (+0.40%)
How to Play PBLS Stock After the Parabilis IPO

Parabilis stock soared on its Nasdaq debut, but a deeper dive suggests PBLS shares could extend gains further through the remainder of 2026.

KLRA : 18.51 (+3.18%)
PBLS : 37.22 (+0.40%)
MRNA : 64.46 (+1.80%)
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing...

PBLS : 37.22 (+0.40%)

Business Summary

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 40.98
2nd Resistance Point 39.90
1st Resistance Point 38.56
Last Price 37.22
1st Support Level 36.14
2nd Support Level 35.07
3rd Support Level 33.73

See More

52-Week High 38.83
Last Price 37.22
Fibonacci 61.8% 33.36
Fibonacci 50% 31.67
Fibonacci 38.2% 29.98
52-Week Low 24.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.